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Introduction {#sec005}
============

Diet therapy, including the energy intake management and protein and salt restriction, is a key aspect of chronic kidney disease (CKD) therapy and makes an important contribution to the maintenance of renal function. Several important guidelines have been proposed regarding the dietary intake of CKD patients. In the clinical setting of CKD management in Japan, energy intake is recommended to be within 25--35 kcal/kg ideal body weight (BW) \[[@pone.0223605.ref001]--[@pone.0223605.ref003]\] and protein intake is recommended to be 0.6--1.0 g/kg ideal BW \[[@pone.0223605.ref001],[@pone.0223605.ref004]--[@pone.0223605.ref006]\]. These recommendations differ according to the stage of CKD, and a salt intake of 3--6 g/day is suggested to be ideal \[[@pone.0223605.ref001],[@pone.0223605.ref007],[@pone.0223605.ref008]\]. Low energy intake has been reported to be associated with deterioration of renal function \[[@pone.0223605.ref009],[@pone.0223605.ref010]\], and increased salt intake could increase the risk of progression of renal dysfunction in CKD patients \[[@pone.0223605.ref011],[@pone.0223605.ref012]\].

Recently, near-infrared spectroscopy (NIRS) has been used as a tool to measure the regional saturation of oxygen (rSO~2~), a marker of tissue oxygenation, in order to clarify the influence of CKD progression on cerebral oxygenation in CKD patients receiving hemodialysis (HD) \[[@pone.0223605.ref013]--[@pone.0223605.ref017]\]. The results of these measurements reflect the status of cognitive impairment because of the relationship of rSO~2~ with the Mini-Mental State Examination scores \[[@pone.0223605.ref016]\] and the Montreal Cognitive Assessment test \[[@pone.0223605.ref017]\]. Furthermore, cerebral rSO~2~ has been shown to decrease with decreasing estimated glomerular filtration rate (eGFR) \[[@pone.0223605.ref017]\]. Therefore, cerebral rSO~2~ may be influenced by the nutritional status of CKD patients, because of the impact of dietary intake on renal function. To date, few reports have investigated the relationship between cerebral oxygenation using NIRS and dietary intake in CKD patients who are not receiving dialysis therapy, and data regarding the association between cerebral rSO~2~ and nutritional status of such patients is limited. This study aimed to investigate the influence of dietary intake and nutritional status on the cerebral oxygenation of CKD patients not receiving dialysis therapy.

Materials and methods {#sec006}
=====================

Patients {#sec007}
--------

In this single-center observational study, CKD patients who met the following criteria were enrolled: (1) all-stage CKD patients not yet requiring dialysis who were followed up in the Division of Nephrology of our hospital, (2) patients who were older than 20 years, (3) patients who received dietary education and nutritional assessment for CKD management, and (4) patients who underwent 24-hour urine collection for the evaluation of salt and protein intake. Exclusion criteria were the following comorbidities: congestive heart failure, chronic obstructive pulmonary disease, apparent neurological disorder, or chronic hypotension (defined as systolic blood pressure \<100 mmHg). [Fig 1](#pone.0223605.g001){ref-type="fig"} shows the flow chart of patient enrollment and analysis.

![Patient flow chart.](pone.0223605.g001){#pone.0223605.g001}

Sixty-seven patients were included in this study (47 men, 20 women; mean age, 65.6 ± 15.6 years). As shown in [Table 1](#pone.0223605.t001){ref-type="table"}, the numbers of patients at each CKD stage were as follows: G1, 1; G2, 1; G3a, 6; G3b, 12; G4, 28; and G5, 19. Causes of chronic renal failure included type 2 diabetes mellitus (32 patients), nephrosclerosis (19 patients), chronic glomerulonephritis (eight patients), and other causes (eight patients). All patients provided written informed consent to participate in this study. This study and its protocols were approved by the Institutional Review Board of Saitama Medical Center, Jichi Medical University, Japan (DAI-RIN 15--104) and conform to the provisions of the Declaration of Helsinki (as revised in Tokyo in 2004).

10.1371/journal.pone.0223605.t001

###### Patient characteristics.

![](pone.0223605.t001){#pone.0223605.t001g}

  ------------------------------------------------------------------------------------------
  Characteristics                                Total patients\
                                                 n = 67
  ---------------------------------------------- -------------------------------------------
  Male/female                                    47/20 (70/30)

  Cerebral rSO~2~ (%)                            55.9 ± 6.6

  CKD stages G1/2/3a/3b/4/5                      1 (1)/1 (1)/6 (9)/12 (18)/28 (42)/19 (28)

  Disease                                        

      Diabetes mellitus                          32 (48)

      Nephrosclerosis                            19 (28)

      Chronic glomerulonephritis                 8 (12)

      Others                                     8 (12)

  Antihypertensive medication                    

      Renin-angiotensin system blocker           41 (61.2)

      Calcium channel blocker                    41 (61.2)

      Beta blocker                               22 (32.8)

      Diuretics (loop and/or thiazide)           23 (34.3)

  Antidiabetic medication                        

      Insulin agent                              9 (13.4)

      Dipeptidyl peptidase-4 inhibitor           17 (25.4)

      Insulin secretagogue                       4 (6.0)

      α-glucosidase inhibitor                    3 (4.5)

      Thiazolidinedione                          3 (4.5)

      Sodium-glucose cotransporter-2 inhibitor   3 (4.5)

  Others                                         

      Vitamin D analog                           10 (14.9)

      Phosphate binder                           6 (9.0)

      Statin                                     21 (31.3)

      Antiplatelet agents                        19 (28.4)

      Erythropoiesis-stimulating agent           19 (28.4)
  ------------------------------------------------------------------------------------------

Categorical data are presented as number (%), continuous data are presented as mean ± standard deviation.

Abbreviations: CKD, chronic kidney disease; rSO~2~, regional oxygen saturation.

Evaluation of patient's renal function {#sec008}
--------------------------------------

For the classification of CKD stages, renal function was evaluated using eGFR based on the serum creatinine concentration (S-Cr), and eGFR was calculated using [Eq 1](#pone.0223605.e001){ref-type="disp-formula"} \[[@pone.0223605.ref018]\]: $$\begin{array}{l}
{eGFR\ \left( {mL/min/1.73\ m^{2}} \right) = 194 \times S‐Cr^{‐1.094} \times age^{‐0.287}\ \left( {for\ men} \right)} \\
{\quad{eGFR\ \left( {mL/min/1.73\ m^{2}} \right) = 194 \times S‐Cr^{‐1.094} \times age^{‐0.287} \times 0.793\ \left( {for\ women} \right).}} \\
\end{array}$$

Method of nutritional assessment {#sec009}
--------------------------------

Patients included in this study were asked to record the total quantity of food and beverages consumed either by weight or in household measures and to record the methods of food preparation. Energy intake was evaluated by dietitians based on each patient's 3-day meal record using the fifth edition of the Japanese Standard Tables of Food Composition published by the Science and Technology Agency of Japan \[[@pone.0223605.ref019]\]. Furthermore, 24-h urine collection was performed to enable evaluation of urinary protein excretion (g/day), urinary urea nitrogen (UUN) excretion, and urinary Na^+^ excretion. The urine collection method was as follows: collection was started in the morning after the first morning urine was discarded. Thereafter, the entire volume of urine was collected in a disposable 3L container. To avoid the possibility of inadequate urine collection, we trained all patients to properly collect their urine samples and emphasized that collection must be initiated at a specific time and completed at the same time the next day. Daily protein and salt intakes were calculated based on the UUN and urinary Na^+^ excretion values obtained from the 24-h urine collection.

Protein intake was calculated using Maroni's equation \[[@pone.0223605.ref020]\], as described in [Eq 2](#pone.0223605.e002){ref-type="disp-formula"}: $$\begin{array}{l}
{Protein\ intake\ \left( g/kg\ ideal\ BW/day \right) = \left( BW\ \left( kg \right) \times 0.031 + UUN \right.} \\
{\left( g/day \right)) \times 6.25 \div ideal\ BW\ \left( kg \right).} \\
\end{array}$$

Salt intake was calculated using [Eq 3](#pone.0223605.e003){ref-type="disp-formula"}: $$Salt\ intake\ \left( {g/day} \right) = urinary\ Na^{+}\ excretion\ \left( {mEq/day} \right) \div 17$$

Furthermore, dietary education was provided by a dietician according to the protocols for nutritional management for CKD therapy in Japan; specifically, sufficient energy intake (25--35 kcal/kg ideal BW/day), protein restriction (0.6--1.0 g/kg ideal BW/day), and salt restriction (3--6 g/day) \[[@pone.0223605.ref001]\]. To evaluate the influence of energy intake, protein restriction, and salt restriction on cerebral oxygenation, we calculated the nutritional markers described in Eqs [4](#pone.0223605.e004){ref-type="disp-formula"} and [5](#pone.0223605.e005){ref-type="disp-formula"}: $$\begin{matrix}
{Energy/protein\ index\ \left( {kcal/kg\ ideal\ BW/g\ protein} \right) = Energy\ intake} \\
{(kcal/kg\ ideal\ BW/day) \div Protein\ intake\ \left( {g/day} \right)} \\
\end{matrix}$$ $$\begin{matrix}
{Energy/salt\ index\ \left( {kcal/kg\ ideal\ BW/g\ salt} \right) = Energy\ intake} \\
{\left( {kcal/kg\ ideal\ BW/day} \right) \div salt\ intake\ \left( {g/day} \right)} \\
\end{matrix}$$

Cerebral oxygenation monitoring and clinical laboratory measurements {#sec010}
--------------------------------------------------------------------

Cerebral rSO~2~ was monitored using an INVOS 5100c saturation monitor (Covidien Japan, Tokyo, Japan), which utilizes NIRS technology. This instrument uses a light-emitting diode, which transmits near-infrared light at two wavelengths (735 and 810 nm), and two silicon photodiodes, which act as light detectors to measure oxygenated and deoxygenated hemoglobin (Hb). The ratio of the oxygenated to total Hb (i.e., oxygenated Hb + deoxygenated Hb) signal strength was read as a single numerical value that represents rSO~2~ \[[@pone.0223605.ref021],[@pone.0223605.ref022]\], and all data were immediately and automatically stored in sequence. The inter-observer variance for this instrument; namely, the reproducibility of the rSO~2~ measurement, has been reported to be acceptable \[[@pone.0223605.ref023]--[@pone.0223605.ref025]\]. Therefore, rSO~2~ is considered a reliable indicator for the estimation of actual cerebral oxygenation. Furthermore, the light paths leading from the emitter to the different detectors share a common part; the 30-mm detector assesses superficial tissues, while the 40-mm detector is used to assess deep tissues. By analyzing the differential signals recorded by the two detectors, the data for cerebral rSO~2~ can be supposed to be obtained from deep tissue, 20--30 mm from the body's surface \[[@pone.0223605.ref026],[@pone.0223605.ref027]\]. Before measurement, patients were asked to sit in the chair for at least 5 min, and an rSO~2~ measurement sensor was attached to the patient's forehead. Thereafter, rSO~2~ was measured at 6-s intervals for 5 min, and the mean value calculated. Blood and urinary samples were also obtained from each patient under ambient conditions. This measurement was performed approximately from 2 h to 4 h after each meal for each patient.

Clinical parameters including Hb, serum creatinine, sodium, potassium, chloride, total protein, serum albumin, urinary protein, urinary urea nitrogen, and urinary sodium concentration were measured in our hospital laboratory.

Statistics {#sec011}
----------

Data are expressed as mean ± standard deviation or median (interquartile range) as appropriate. Urinary protein excretion did not show normal distribution, and this variable was transformed using the natural log (ln). Correlations between cerebral rSO~2~ and each clinical parameter, including nutritional parameters, were evaluated using Pearson's correlation coefficient and linear regression analysis. Variables with a p value below 0.10 in simple linear regression analysis and plausible confounding factors were included in multivariable linear regression analysis to identify factors affecting cerebral rSO~2~ in CKD patients. Statistical significance was accepted at p \< 0.05. All analyses were performed using SPSS Statistics for Windows, version 19.0 (IBM Corp., NY, USA).

Results {#sec012}
=======

The mean cerebral rSO~2~ values of the CKD patients in this study were 55.9 ± 6.6%, and these were significantly positively correlated with Hb level, serum albumin concentration, energy intake, and energy/salt index. Cerebral rSO~2~ was negatively correlated with body mass index ([Table 2](#pone.0223605.t002){ref-type="table"}). Cerebral rSO~2~ was negatively correlated with salt intake (r = -0.228, p = 0.064) and positively correlated with energy/protein index (r = 0.203, p = 0.099), although these correlations were not significant. [Fig 2](#pone.0223605.g002){ref-type="fig"} illustrates the significant correlation between cerebral rSO~2~ and energy intake (r = 0.388, p = 0.001).

![Correlation between cerebral oxygen saturation and energy intake in advanced chronic kidney disease patients.\
Equation of trend line (representing cerebral oxygen saturation) = 0.614 × energy intake + 39.1; r = 0.388, p = 0.001. Abbreviations: BW, body weight; rSO~2~, regional saturation of oxygen.](pone.0223605.g002){#pone.0223605.g002}

10.1371/journal.pone.0223605.t002

###### Correlation between cerebral oxygen saturation and clinical parameters, including dietary intake and nutritional parameters, in simple linear regression analysis.

![](pone.0223605.t002){#pone.0223605.t002g}

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Characteristics                                         Total patients\   vs. cerebral rSO~2~ values in simple linear regression   
                                                          n = 67                                                                     
  ------------------------------------------------------- ----------------- -------------------------------------------------------- ---------------------------------------------
                                                          r                 *p* value                                                

  Age (years)                                             65.6 ± 15.6       -0.119                                                   0.338

  Body mass index (kg/m^2^)                               24.8 ± 5.2        -0.245                                                   0.045[\*](#t002fn002){ref-type="table-fn"}

  Systolic blood pressure (mmHg)                          138 ± 18          -0.037                                                   0.764

  Diastolic blood pressure (mmHg)                         77 ± 14           0.059                                                    0.633

  Sat O~2~ (%)                                            97.9 ± 0.7        -0.006                                                   0.961

  Laboratory findings                                                                                                                

      Hb (g/dL)                                           11.9 ± 1.8        0.271                                                    0.027[\*](#t002fn002){ref-type="table-fn"}

      eGFR (mL/min/1.73m^2^)                              25.5 ± 17.1       0.201                                                    0.104

      Na (mEq/L)                                          139 ± 3           -0.006                                                   0.963

      K (mEq/L)                                           4.7 ± 0.6         0.065                                                    0.602

      Cl (mEq/L)                                          107 ± 4           -0.130                                                   0.296

      Total protein (g/dL)                                7.0 ± 0.6         -0.010                                                   0.938

      Serum albumin (g/dL)                                3.9 ± 0.4         0.264                                                    0.031[\*](#t002fn002){ref-type="table-fn"}

      Urinary protein excretion (g/g-Cr)                  1.0 (0.2--1.2)                                                             

      ln (urinary protein excretion)                      -0.8 ± 1.4        -0.125                                                   0.314

  Nutritional markers                                                                                                                

      Energy intake (kcal/kg ideal BW/day)                27.0 ± 4.2        0.388                                                    0.001 [\*](#t002fn002){ref-type="table-fn"}

      Protein intake (g/ kg ideal BW/day)                 0.8 ± 0.2         -0.036                                                   0.775

      Salt intake (g/day)                                 6.3 ± 2.3         -0.228                                                   0.064

      Energy/protein index (kcal/kg ideal BW/g-protein)   0.7 ± 0.2         0.203                                                    0.099

      Energy/salt index (kcal/kg ideal BW/g-salt)         4.9 ± 2.1         0.332                                                    0.006 [\*](#t002fn002){ref-type="table-fn"}
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Continuous data are presented as mean ± standard deviation.

\*Statistically significant.

Abbreviations: BW, body weight; eGFR, estimated glomerular filtration rate; Hb, hemoglobin; rSO~2~, regional oxygen saturation.

Results of multivariable linear regression analysis are presented in Tables [3](#pone.0223605.t003){ref-type="table"} and [4](#pone.0223605.t004){ref-type="table"}. For Model 1; body mass index, Hb level, serum albumin concentration, salt and energy intake as variables with p values below 0.10, as well as eGFR, serum sodium concentration, and protein intake as confounding factors, were included in multivariable linear regression analysis. As shown in [Table 3](#pone.0223605.t003){ref-type="table"}, cerebral rSO~2~ was independently associated with energy intake (standardized coefficient: 0.370) and serum albumin concentration (standardized coefficient: 0.236). The energy/protein index and energy/salt index were included in place of salt, protein, and energy intake as variables in Model 2 to avoid collinearity with Model 1. As a result, energy/salt index (standardized coefficient: 0.343) and Hb level (standardized coefficient: 0.284) were also identified as factors affecting cerebral rSO~2~ in this study ([Table 4](#pone.0223605.t004){ref-type="table"}).

10.1371/journal.pone.0223605.t003

###### Multivariable linear regression analysis in Model 1 using variables including salt, protein, and energy intake as a nutritional marker: independent factors of cerebral oxygen saturation.

![](pone.0223605.t003){#pone.0223605.t003g}

                        Multivariable linear regression   
  --------------------- --------------------------------- ---------------------------------------------
      Body mass index   -0.152                            0.201
      Hb                0.205                             0.078
      eGFR              0.179                             0.118
      Na                0.052                             0.659
      Serum albumin     0.236                             0.039 [\*](#t003fn001){ref-type="table-fn"}
      Salt intake       -0.166                            0.155
      Protein intake    0.011                             0.923
      Energy intake     0.370                             0.002 [\*](#t003fn001){ref-type="table-fn"}

\*Statistically significant.

Abbreviations: eGFR, estimated glomerular filtration rate

Hb, hemoglobin; rSO~2~, regional oxygen saturation.

10.1371/journal.pone.0223605.t004

###### Multivariable linear regression analysis in Model 2 using variables including energy/protein index and energy/salt index as a nutritional marker: independent factors of cerebral oxygen saturation.

![](pone.0223605.t004){#pone.0223605.t004g}

                             Multivariable linear regression   
  -------------------------- --------------------------------- ---------------------------------------------
      Body mass index        -0.144                            0.228
      Hb                     0.284                             0.014[\*](#t004fn001){ref-type="table-fn"}
      eGFR                   0.121                             0.417
      Na                     0.069                             0.560
      Serum albumin          0.191                             0.128
      Energy/protein index   0.115                             0.409
      Energy/salt index      0.343                             0.003 [\*](#t004fn001){ref-type="table-fn"}

\*Statistically significant.

Abbreviations: eGFR, estimated glomerular filtration rate

Hb, hemoglobin; rSO~2~, regional oxygen saturation.

Discussion {#sec013}
==========

The present study focused on the association between cerebral oxygenation and nutritional status including indices of dietary intake in CKD patients who were not receiving dialysis. These results confirmed that cerebral rSO~2~ levels are independently associated with energy intake and serum albumin concentration in Model 1 and with energy/salt index and Hb level in Model 2.

It has previously been reported that cerebral rSO~2~ values of healthy individuals are nearly 70%, whereas those in patients undergoing HD are lower at around 50% \[[@pone.0223605.ref014],[@pone.0223605.ref015]\]. Furthermore, cerebral rSO~2~ values have been shown to decrease according to the progression of renal dysfunction \[[@pone.0223605.ref017]\]. In this study, cerebral rSO~2~ values were found to lie between those of healthy individuals and patients undergoing HD, consistent with the previous report \[[@pone.0223605.ref017]\].

In both models for determination of modifiable factors independently associated with cerebral rSO~2~, energy intake was found to be the most important factor. Adequate dietary intake and nutritional status have well-understood impacts on brain functions, and the mechanisms involved in the transfer of energy from foods to neurons are likely to be fundamental to the control of brain function \[[@pone.0223605.ref028]\]. Therefore, the effect of energy intake on cerebral oxygenation might be explained by the fact that this factor is essential for the maintenance of brain function via the energy supply to brain tissues, including cerebral microcirculation. Furthermore, it has been recently reported that the brain-gut axis is very important in the control of dietary intake \[[@pone.0223605.ref029]\]. Ghrelin, which is secreted primarily by epithelial cells of the stomach, stimulates food intake and is strongly associated with the regulation of energy homeostasis \[[@pone.0223605.ref030],[@pone.0223605.ref031]\]. In addition, beneficial effects on vascular function and cardiovascular disease have been reported in response to ghrelin, via the stimulation of nitric oxide production and prevention of endothelial cell apoptosis \[[@pone.0223605.ref032]--[@pone.0223605.ref035]\]. Ghrelin might, therefore, play an important role in the maintenance of microcirculation and oxygenation in systemic tissues. The changes that occur in circulating ghrelin levels in the case of CKD and the effects of ghrelin in this context remain controversial \[[@pone.0223605.ref036],[@pone.0223605.ref037]\]. However, the administration of ghrelin to patients with advanced CKD undergoing dialysis leads to increased appetite and food intake and consequent changes in energy balance \[[@pone.0223605.ref038],[@pone.0223605.ref039]\]. Based on these results, ghrelin might simultaneously influence energy intake and systemic oxygenation status, including that of the brain, via the regulation of energy homeostasis and prevention of microcirculation impairment, even in patients with advanced CKD. The results presented here of the significant and positive association between cerebral rSO~2~ and energy intake may therefore reflect the influence of the brain-gut axis, including the effects of ghrelin. However, the effects of ghrelin were not directly investigated in this study; therefore, we cannot comment on the association between cerebral oxygenation, energy intake, and the effects of ghrelin.

Salt intake has previously been reported to be associated with the progression of renal dysfunction \[[@pone.0223605.ref011],[@pone.0223605.ref012]\] and cerebrovascular disease including cognitive impairments \[[@pone.0223605.ref040],[@pone.0223605.ref041]\]. Recently, studies in mice have shown that high salt diets induce marked cerebral hypoperfusion and deterioration of cerebral microcirculation associated with endothelial dysregulation via the suppression of endothelial nitric oxide. This suppression was dependent on the high salt diet-induced interleukin-17 response \[[@pone.0223605.ref042]\], and changes in cerebral blood flow that are affected by salt intake are proposed as a new brain-gut axis. Therefore, according to the degree of increase in salt intake, cerebral oxygenation could be expected to worsen due to decreased oxygen supply induced by the deterioration of cerebral microcirculation. In this study, the mean salt intake was found to be 6.3 ± 2.3 g/day (ranging from 2.6--14.0 g/day), even after dietary education was provided, and was negatively correlated with cerebral rSO~2~. Furthermore, a significant association between cerebral rSO~2~ and energy/salt index was confirmed. Based on this result, salt restriction might be an approach to maintain cerebral oxygenation in addition to sufficient energy intake in the clinical setting. However, this study could not determine a significant relationship between salt intake and cerebral rSO~2~ values; therefore, further study is needed to confirm the effect of salt intake on cerebral oxygenation and microcirculation.

Regarding the association between cerebral rSO~2~ and nutritional parameters in this study, serum albumin concentration and Hb level were significantly associated with cerebral rSO~2~ in multivariate linear regression analysis. Serum albumin concentration, the main determinant of colloid osmotic pressure in vessels, plays an important role in maintaining microcirculation in systemic tissues via the movement of body fluids, mainly between the vessels and interstitium \[[@pone.0223605.ref043]\]. Furthermore, consistent with the present study, serum albumin concentration has been reported to be significantly associated with cerebral oxygenation in patients with all stages of CKD, as well as patients undergoing HD \[[@pone.0223605.ref015],[@pone.0223605.ref017]\]. In addition, Hb is an important factor in oxygen supply to the peripheral tissues and organs, including the brain; therefore, Hb level is expected to be associated with tissue rSO~2~. Thus far, in various clinical settings including hematology \[[@pone.0223605.ref044]\], surgery \[[@pone.0223605.ref045]\], pediatrics \[[@pone.0223605.ref046]--[@pone.0223605.ref048]\], and HD therapy \[[@pone.0223605.ref049]\], cerebral rSO~2~ has been shown to significantly increase in line with the increasing Hb levels following blood transfusion. On the other hand, it has been reported that there is no relationship between Hb concentration and cerebral rSO~2~ values in HD patients with well-maintained Hb levels \[[@pone.0223605.ref015],[@pone.0223605.ref017]\]. In this study, it is likely that Hb levels were well-maintained (the mean value was found to be 11.9 ± 1.8 g/dL); however, the values were widely distributed, from 7.1--16.0 g/dL. This study might, therefore, confirm the association between cerebral rSO~2~ and Hb levels, because the wide distribution of cerebral rSO~2~ values reflects the wide distribution of Hb levels.

This study had several limitations which should be noted. First, it was limited by its relatively small sample size. Second, examination of the relationship of cerebral oxygenation with cognitive function could be considered to be important. However; in this study, cognitive assessment could not be performed because of the limits of the medical examination time for each patient. Thus, we cannot comment on the association between cerebral oxygenation and cognitive function at the present time. Third, in this study, salt intake was calculated using urinary Na^+^ excretion based on the 24-h urine collection for each patient. These values were positively correlated to those calculated in each patient's 3-day meal record (salt intake based on the 24-h urine collection: 6.3 ± 2.3 g/day vs salt intake based on each patient's 3-day meal record: 6.1 ± 1.6 g/day, r = 0.719, p\< 0.001). However, due to fluctuations in daily salt intake, the values based on the 24-h urine collection may not fully reflect the constant daily salt intake for each patient. Finally, no relationships were detected between cerebral oxygenation and markers of renal function, although cerebral rSO~2~ has been reportedly to be associated with eGFR in patients with all stages of CKD \[[@pone.0223605.ref017]\]. The patients included in this study mainly suffered from severe advanced CKD, and those with CKD stage 4 or 5 represented around 70% of the cohort (47 out of 67 included patients). This proportion is significantly different to that of the previous report (40% of the study population had CKD stage 4 or 5) \[[@pone.0223605.ref017]\]. This might be one of the reasons for the different observations of cerebral oxygenation with regards to renal function; however, the precise reason remains unclear. Therefore, additional studies are needed to confirm the association between cerebral oxygenation and clinical parameters including dietary intake and nutritional parameters, in addition to the examination of cognitive function.

In conclusion, cerebral rSO~2~ is affected by energy intake and the energy/salt index in addition to serum albumin concentrations and Hb levels. Therefore, sufficient energy intake with adequate salt restriction is important to prevent the deterioration of cerebral oxygenation and might contribute to the maintenance of cognitive function in addition to the prevention of renal dysfunction in CKD patients.
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Reviewer \#1: Yes

\*\*\*\*\*\*\*\*\*\*

2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: I consider the paper to ve of a very good quality, I only have a few minor comments:

\- introduction, reference 16 (Kovarova et al.): The study reported a significant rekation of rSO2 values with Montreal Cognitive Assessment, which is more specific for cognitive impairment in ESRD patients, not with MMSE

\- results, lines 1 and 2: \... rSO2 values were\... (there is "was" used incorrectly in the article)

\- I would consider presentation of rSO2 values in different patient groups according to CKD stage interesting.

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.

10.1371/journal.pone.0223605.r002

Author response to Decision Letter 0
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Response to academic editors' and reviewers' comments.

We appreciate your careful review and hope that we have satisfactorily addressed each of your comments in the section below.

Academic editor:

Comment 1:

The authors discussed possible effect of ghrelin on oxygenation. It is an acute response after meal. In which timing after meal, did the authors evaluate brain oxygenation?

Response 1:

Thank you for your comment. It was previously reported that ghrelin might contribute to the positive balance in energy intake and systemic circulatory stability and potentially improve systemic tissue oxygenation, including in the brain. Therefore, we discussed ghrelin's potential effect on the energy intake and cerebral oxygenation in patients with CKD in our discussion section in the main manuscript. However, to date, few studies have investigated these relationships, and further studies will be needed to confirm ghrelin's association with oxygenation in patients with CKD. Fasting ghrelin levels were high, whereas postprandial ghrelin levels rapidly decreased; therefore, the timing of cerebral oxygenation measurements is of great importance. As kindly suggested by the editor, we have added a statement regarding the timing of cerebral oxygenation measurements in the materials and methods section as follows:

Page 6, Lines 25-26:

"This measurement was performed approximately from 2 h to 4 h after each meal for each patient."

Comment 2:

There are possible correlations with salt intake and they discussed that in animal study, salt intake affect brain oxygenation. In animal study, salt loading is a chronic load and possibly salt induces inflammation or endothelial dysfunction. In contrast, in the current study authors evaluated salt intake merely one day evaluation and we can not know the cohorts take salt in constant level.

Response 2:

We appreciate your thoughtful comment on this subject. As mentioned, daily salt intake fluctuates in each patient and we cannot conclude that values obtained in this study fully reflect the constant daily salt intake by each patient. However, these values were confirmed to significantly and positively correlate with those calculated in each patient's 3-day meal record (salt intake based on the 24-h urine collection: 6.3 ± 2.3 g/day vs salt intake based on each patient's 3-day meal record: 6.1 ± 1.6 g/day, r = 0.719, p\< 0.001). To address this question, repeated evaluation of salt intake based on the 24-h urine collection would be necessary for each patient along with confirmation of these values in a clinical setting. We added a paragraph that refers to these limitations in the revised manuscript, as follows:

Page 11, Lines 22-29:

"Third, in this study, salt intake was calculated using urinary Na+ excretion based on the 24-h urine collection for each patient. These values were positively correlated to those calculated in each patient's 3-day meal record (salt intake based on the 24-h urine collection: 6.3 ± 2.3 g/day vs salt intake based on each patient's 3-day meal record: 6.1 ± 1.6 g/day, r = 0.719, p\< 0.001). However, due to fluctuations in daily salt intake, the values based on the 24-h urine collection may not fully reflect the constant daily salt intake for each patient."

Comment 3:

Half of cohort are diabetic and two thirds of cohort is medicated for hypertension. Is there any effect of antidiabetic drugs, control of diabetes or blood pressure? In table 1, authors should show the distribution of antidiabetic drugs.

Response 3:

We have taken your suggestion under consideration and added the distribution of antidiabetic drugs in Table 1, as follows:

Antidiabetic medication

Insulin agent 9 (13.4)

Dipeptidyl peptidase-4 inhibitor 17 (25.4)

Insulin secretagogue 4 (6.0)

α-glucosidase inhibitor 3 (4.5)

Thiazolidinedione 3 (4.5)

Sodium-glucose cotransporter-2 inhibitor 3 (4.5)

In patients with DM, plasma glucose was 137 ± 48 mg/dL and HbA1c was 6.7 ± 0.9%. Cerebral rSO2 did not show a significant correlation with levels of plasma glucose (r = -0.091, p = 0.666) or HbA1c (r = 0.130, p = 0.565). As shown in Table 2, cerebral rSO2 did not show a significant correlation with systolic BP (r = -0.037, p = 0.764) or diastolic BP (r = 0.059, p = 0.633). Furthermore, in patients with DM, systolic BP was 138 ± 21 mmHg and diastolic BP was 75 ± 15 mmHg. For these patients, cerebral rSO2 did not show a significant correlation with systolic BP (r = 0.136, p = 0.458) or with diastolic BP (r = 0.070, p = 0.704).

 

Reviewer 1:

Comment 1:

\- introduction, reference 16 (Kovarova et al.): The study reported a significant rekation of rSO2 values with Montreal Cognitive Assessment, which is more specific for cognitive impairment in ESRD patients, not with MMSE.

Response 1:

Thank you for your careful review of our manuscript and detection of this incorrect description. We have corrected it in the Introduction section, as follows:

Page 3, Lines 20-21:

"The results of these measurements reflect the status of cognitive impairment because of the relationship of rSO2 with the Mini-Mental State Examination scores \[16\] and the Montreal Cognitive Assessment test \[17\]."

Comment 2:

\- results, lines 1 and 2: \... rSO2 values were\... (there is "was" used incorrectly in the article)

Response 2:

Thank you for your diligent proofreading of our manuscript. We have now corrected the description in the results section, as follows:

Page 8, Lines 3-4:

"The mean cerebral rSO2 values of the CKD patients in this study were 55.9 ± 6.6%, and these were significantly positively correlated with Hb level, serum albumin concentration, energy intake, and energy/salt index."

Comment 3:

\- I would consider presentation of rSO2 values in different patient groups according to CKD stage interesting.

Response 3:

Thank you for your thoughtful comment. We agree with your suggestion. In this study, cerebral rSO2 values in CKD stages G1 to G3b (n = 20), G4 (n = 28), and G5 (n = 19) were 57.3 ± 6.2%, 55.9 ± 6.9%, and 53.2 ± 6.3%, respectively, and no significant differences were found among the 3 groups using a one-way ANOVA analysis (p = 0.113). However, under the assumption of an effect size of 0.25, alpha error probability of 0.05, and statistical power of 0.80, comparison among 3 groups using ANOVA would require 159 patients in total (53 patients per group). In our study, the number of the patients is currently insufficient to accurately perform these analyses. Therefore, further studies including larger patient population will be needed to confirm these results.
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Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: All comments have been addressed

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.
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5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes
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6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)
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